Comparative Pharmacology
Head-to-head clinical analysis: CLOCORTOLONE PIVALATE versus LOCOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOCORTOLONE PIVALATE versus LOCOID.
CLOCORTOLONE PIVALATE vs LOCOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clocortolone pivalate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Topical: Apply a thin film to affected area once or twice daily. Not for ophthalmic use. Maximum duration of 2 weeks per course.
Topical: Apply a thin layer to affected area once or twice daily. Maximum: 30-60 g per week. Not for use >2 consecutive weeks or on >50% of body surface.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours (range 1-4 hours), reflecting rapid clearance; clinical duration exceeds half-life due to tissue binding.
Terminal elimination half-life: 30-40 hours; clinically significant for once-daily dosing and prolonged action
Primarily renal (approximately 80%) as glucuronide and sulfate conjugates; minor biliary/fecal excretion (20%).
Renal (approximately 60-70%) as conjugated metabolites; biliary/fecal (approximately 20-30%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid